Hummingbird Ventures

Hiring analysts globally. Apply by Jan 5. hummingbird.vc/analyst-program

Continued congratulations to Anton, Fabian, and the team! @lovable is on a tear, raising $200m at a $1.8b valuation only 8 months after launching. Already changing the fabric of the internet, Lovable makes it possible for anyone to build software 🚀 forbes.com/sites/iainmart…

@lovable is on a tear, raising $200m at a $1.8b valuation only 8 months after launching. Already changing the fabric of the internet, Lovable makes it possible for anyone to build software. Congratulations to Anton, Fabian, and the whole team! 🚀forbes.com/sites/iainmart…

We are launching our first SF-based cohort of our Analyst Program. This is a two year program to be fully immersed in global, early-stage investing. Applications are open until April 25. hummingbird.vc/analyst-program

Building products takes too long. We started Lovable to fix this. Today, we're officially launching the world’s first AI Full Stack Engineer Lovable reliably replicates the capabilities of a full stack engineer and handles everything from design to database operations by integrating with Supabase. So what’s new exactly? 🧵

We’re thrilled to announce the launch of Hummingbird’s Analyst Program—a unique, two-year venture into the world of early-stage, high conviction investing. Applications close on November 22nd. More details: hummingbird.vc/analyst-program

Today we announce a series of milestones: We're thrilled to share our $60M Series B funding, led by @singular__ including @S32_VC, @redalpine, @trueventures & @HummingbirdVC! We'll scale data collection & enhance AI with this oversubscribed round. Read more: bit.ly/47XvT3K

t - 10 days shorturl.at/wnsAm

We're thrilled to announce that Automata has secured $40m in our most recent funding round, led by @_DimensionCap with participation from new and returning investors. We can't wait to see more life science labs adopting complete automation platforms like LINQ!

The current model for deep space transport is painfully expensive because it depends on throwing rockets away for almost all missions. Missions could be 10x cheaper if they had access to propellants produced on the Moon and Mars. That’s what we are solving at Starpath. 1/

We believe the future of generalisable protein design is contextualised, uniform & ML-ready datasets combined with a new era of complementary ML models. This is exactly what we're laser-focussed building, so it's great to see our work at @Basecamp_Res featured in @NatureBiotech!

Amber Bio pre-print alert 🚨 @jacobborrajo @themicrobeguy et al. show us how to introduce multi-Kb inserts into endogenous mRNA by co-opting the spliceosome 1/n biorxiv.org/content/10.110…

Thrilled to share a preview of some of the exciting work happening at Amber Bio! Today we introduce a new CRISPR editing modality, Splice Editing, which enables multi-kilobase RNA edits in human cells. (1/n) biorxiv.org/content/10.110…

⚡️ @Basecamp_Res is looking for a Marketing Lead & creatives/science communicators to craft their storytelling & share more about their work: unlocking the potential of our planet's unexplored biodiversity to build sustainable biotechnology. Ping me if that sounds interesting ⚡️

#CantosVentures' Amee Kapadia and #HummingbirdVentures' Pablo Lubroth share key takeaways from their recently released report on the future of #biology and talk about the driving forces changing the way biology is used and studied. #NYSEFloorTalk

Today we welcome Kim Branson, SVP & Global Head of AI/ML at GSK to our Board of Directors. A leader in the application of AI to drug disc & dev, Kim will bolster our leading position at the interface of ML and biotech as we unlock Nature’s chemistry for modern discovery workflows

Revitalising my blog with some thoughts on generative AI in fintech. open.substack.com/pub/chainewsle…

We are extremely pleased to be featured in the "extreme biology" group of Decoding Bio's first industry snapshot, out now. We believe in the power of Nature’s Biochemistry to solve our industry’s toughest problems & are excited to be part of this larger movement of companies.

We’re incredibly excited to publish the inaugural edition of the Decoding Bio Snapshot. Several months in the making, it profiles 40 companies operating at the intersection of computation and biology, ranging from pre-seed to publicly traded. snapshot.decodingbio.com

Back with another longform piece (!!) This is the second in a series of guides to help LPs navigate the emerging deep tech venture landscape. "Deep tech" has big tailwinds & an investment bottleneck at seed due to the technical/market barriers for GPs. (link in bio bc Elon)